ClinicalTrials.gg
CompletedNCT02564198Updated Aug 17, 2021Results posted

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

A Phase 1 interventional study of Ramucirumab in Pediatric Solid Tumor, Refractory Tumor and Recurrent Tumor, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 12 Months to 21 Years. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
12 Months to 21 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

02

Conditions studied

  • Pediatric Solid Tumor
  • Refractory Tumor
  • Recurrent Tumor
  • CNS Malignancies

Keywords

  • relapsed pediatric solid tumors
  • unspecified childhood solid tumor
  • brain and central nervous system tumors
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 29 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A: participants with recurrent or non-CNS solid tumors
  • Part B: participants with recurrent or refractory CNS tumors
  • Measurable or evaluable disease
  • No other therapeutic options
  • Performance Status: ≥50% for participants >16 years and Lansky ≥50 for participants ≤16 years

Exclusion criteria

Exclusion Criteria:

  • Active or recent history of serious bleeding events
  • Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
  • Active or recent history of hypertensive crisis or hypertensive encephalopathy
  • Active non-healing wound or bone fracture
  • History of solid organ transplant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Ramucirumab

    (Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle. (Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.

    Drug: Ramucirumab

Interventions

  • Administered IV

    Also known as: LY3009806, IMC-1121B, Cyramza

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab

    A DLT is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: 1. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \>7 days 4. Grade ≥3 thrombocytopenia with bleeding 5. Grade ≥3 nausea/vomiting or diarrhea\>72 hours with adequate antiemetic and other supportive care 6. Grade ≥3 fatigue ≥1 week 7. Grade ≥3 electrolyte abnormality that lasts\>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT. 8. Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart.

    Time frame: Baseline to Study Completion (Up to 42 Months)

  2. Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

    Population Pharmacokinetics (PK): Minimum observed plasma concentration of Ramucirumab.

    Time frame: Predose, Cycle 1 Day 1 (end of infusion (EOI), 1 hour after EOI) and Cycle 1 Day 43 (1 hour after EOI)

  3. Number of Participants With Anti-Ramucirumab Antibodies

    Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

    Time frame: Predose Cycle 1 Day 1 through Follow-Up (Up to 42 Months)

Secondary outcomes

  1. Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)

    Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline to Date of Objective Disease Progression (Up to 42 Months)

  2. Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)

    Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline to Date of Objective Disease Progression (Up to 42 Months)

  3. Duration of Response (DOR)

    DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 42 Months)

  4. Overall Survival

    Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.

    Time frame: Baseline to Date of Death from Any Cause (Up to 42 Months)

07

Results

Posted Aug 17, 2021

Participant flow

Participant flow — Overall Study
Milestone8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
Started8156
Received at least 1 dose of study drug8156
Completed6106
Not completed250
Withdrew: Withdrawal by subject240
Withdrew: Adverse event010

Outcome measures

PrimaryPart A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab

A DLT is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: 1. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \>7 days 4. Grade ≥3 thrombocytopenia with bleeding 5. Grade ≥3 nausea/vomiting or diarrhea\>72 hours with adequate antiemetic and other supportive care 6. Grade ≥3 fatigue ≥1 week 7. Grade ≥3 electrolyte abnormality that lasts\>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT. 8. Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart.

Time frame:
Baseline to Study Completion (Up to 42 Months)
Reported as:
Number · Participants
Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab
Participants8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)
Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab11
PrimaryPopulation Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab

Population Pharmacokinetics (PK): Minimum observed plasma concentration of Ramucirumab.

Time frame:
Predose, Cycle 1 Day 1 (end of infusion (EOI), 1 hour after EOI) and Cycle 1 Day 43 (1 hour after EOI)
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Population Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
microgram per milliliter (µg/mL)8 mg/kg Ramucirumab12 mg/kg Ramucirumab
Cycle 1 Day 130.0 ± 3248.3 ± 41
Cycle 1 Day 4353.6 ± 3180.2 ± 44
PrimaryNumber of Participants With Anti-Ramucirumab Antibodies

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.

Time frame:
Predose Cycle 1 Day 1 through Follow-Up (Up to 42 Months)
Reported as:
Number · participants
Number of Participants With Anti-Ramucirumab Antibodies
participants8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
Number of Participants With Anti-Ramucirumab Antibodies000
SecondaryOverall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)

Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline to Date of Objective Disease Progression (Up to 42 Months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)
Percentage of participants8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)0 (0.0 to 41.0)0 (0.0 to 23.2)0 (0.0 to 45.9)
SecondaryPercentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline to Date of Objective Disease Progression (Up to 42 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)
Percentage of participants8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD): Disease Control Rate (DCR)62.5 (29.0 to 96.3)40.0 (17.7 to 71.1)33.3 (4.3 to 77.7)
SecondaryDuration of Response (DOR)

DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 42 Months)

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.

Time frame:
Baseline to Date of Death from Any Cause (Up to 42 Months)
Reported as:
Median · Months
Overall Survival
Months8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
Overall SurvivalNA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Baseline, up to 4 years 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
8 mg/kg Ramucirumab (Part A)0/8 (0%)3/8 (37.5%)8/8 (100%)
12 mg/kg Ramucirumab (Part A)0/15 (0%)7/15 (46.7%)15/15 (100%)
12 mg/kg Ramucirumab (Part B)0/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
Event8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
PyrexiaGeneral disorders0/83/150/6
Kidney infectionInfections and infestations0/80/151/6
HeadacheNervous system disorders1/80/151/6
SeizureNervous system disorders0/80/151/6
DyspnoeaRespiratory, thoracic and mediastinal disorders0/82/150/6
HypoxiaRespiratory, thoracic and mediastinal disorders0/82/150/6
HypertensionVascular disorders1/80/150/6
HypotensionVascular disorders1/80/150/6
Abdominal painGastrointestinal disorders0/81/150/6
InfectionInfections and infestations0/81/150/6
Most frequent other events
Showing 10 of 146
Most frequent other events
Event8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)
Aspartate aminotransferase increasedInvestigations1/812/152/6
Lymphocyte count decreasedInvestigations4/82/154/6
AnaemiaBlood and lymphatic system disorders2/89/152/6
FatigueGeneral disorders1/88/151/6
NauseaGastrointestinal disorders4/87/151/6
Alanine aminotransferase increasedInvestigations1/86/153/6
Haemoglobin increasedInvestigations1/81/153/6
HypermagnesaemiaMetabolism and nutrition disorders0/84/153/6
VomitingGastrointestinal disorders3/87/152/6
Decreased appetiteMetabolism and nutrition disorders1/87/151/6

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)Total
Mean15.8 ± 3.3311.9 ± 5.599.7 ± 5.912.5 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)Total
Female46212
Male49417
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)Total
Hispanic or Latino2226
Not Hispanic or Latino612422
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0213
White712423
More than one race0000
Unknown or Not Reported1113
Region of Enrollment
Region of Enrollment(Participants)8 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part A)12 mg/kg Ramucirumab (Part B)Total
United States815629
08

Study locations

21 sites
  • Childrens Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Children's Oncology Group
    Monrovia, California 91016, United States
  • Childrens Hospital of Orange County
    Orange, California 92868, United States
  • University of California, San Francisco
    San Francisco, California 94158, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010-2970, United States
  • Children's Healthcare of Atlanta at Scottish Rite
    Atlanta, Georgia 30322, United States
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Mark O Harfield-Warren Grant Magnuson Clinical Center
    Bethesda, Maryland 20892, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota Hospital
    Minneapolis, Minnesota 55455, United States
  • Washington University Medical School
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • St Jude Childrens Research Hospital
    Memphis, Tennessee 38105, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital Research Foundation
    Seattle, Washington 98105, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jul 2019, 43 months.

Results were first posted in Aug 2021, 2 years 1 month after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 43 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2015
First posted
Sep 30, 2015
StartActual
Dec 11, 2015
Primary completionActual
Jul 16, 2019
CompletionActual
Jul 16, 2019
Results first posted
Aug 17, 2021
Last update
Aug 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02564198
Responsible party
Sponsor
First posted
Sep 30, 2015
Start date
Dec 11, 2015
Primary completion
Jul 16, 2019
Completion
Jul 16, 2019
Results posted
Aug 17, 2021
Last update
Aug 17, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion